AGC Biologics recognised for innovations in Cell Line Development

KUALA LUMPUR, Oct 14 (Bernama) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has been named a 2022 Leading Innovator in Mammalian Cell Line Development for the USA by Acquisition International.

According to a statement, recipients of this award are selected through a merit-based system that requires evidence of significant achievements and a clear commitment to innovation.

“AGC Biologics’ pursuit of constant innovation can be seen with the global implementation of new modern approaches in our cell line development capabilities for increased protein production.

“We are investing in new technologies for high-throughput screening, increased DNA integration, and high-producing cell lines to maximise the output of our CLD programmes to give client’s the best product possible,” said Sr. Development Scientist, PD R&D Center for AGC Biologics, Kayla Bean.

AGC Biologics has a Cell Line Development programme backed by several decades of scientific expertise and research.

The company’s global network of sites has established more than 200 mammalian and microbial cell culture-based products.

The CDMO’s cell line development services offer seamless process transfer to cGMP manufacturing, short timelines, and the ability to meet finite budgets.

Further, AGC Biologics’ in-house quality and regulatory teams ensure cell line development projects are ready for any stage, across any regulatory market, anywhere in the world.

AGC Biologics currently has four locations offering cell line development services in Seattle, WA and Boulder, CO, USA, Copenhagen, Denmark, and Chiba, Japan.

More details at www.agcbio.com.

-- BERNAMA